| B cells and tertiary lymphoid structures promote immunotherapy response BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ... Nature 577 (7791), 549-555, 2020 | 2082 | 2020 |
| Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ... Nature medicine 24 (11), 1655-1661, 2018 | 815 | 2018 |
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ... Nature communications 5 (1), 5712, 2014 | 749 | 2014 |
| Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 … EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ... The lancet oncology 20 (7), 948-960, 2019 | 480 | 2019 |
| Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases F Weeber, M Van De Wetering, M Hoogstraat, KK Dijkstra, O Krijgsman, ... Proceedings of the National Academy of Sciences 112 (43), 13308-13311, 2015 | 476 | 2015 |
| Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, ... Nature medicine 27 (2), 256-263, 2021 | 276 | 2021 |
| Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy K Renner, C Bruss, A Schnell, G Koehl, HM Becker, M Fante, ... Cell reports 29 (1), 135-150. e9, 2019 | 272 | 2019 |
| CopywriteR: DNA copy number detection from off-target sequence data T Kuilman, A Velds, K Kemper, M Ranzani, L Bombardelli, M Hoogstraat, ... Genome biology 16, 1-15, 2015 | 233 | 2015 |
| Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold DW Vredevoogd, T Kuilman, MA Ligtenberg, J Boshuizen, KE Stecker, ... Cell 178 (3), 585-599. e15, 2019 | 218 | 2019 |
| Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors J Boshuizen, LA Koopman, O Krijgsman, A Shahrabi, EG van den Heuvel, ... Nature medicine 24 (2), 203-212, 2018 | 217 | 2018 |
| Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma JL Vos, JBW Elbers, O Krijgsman, JJH Traets, X Qiao, AM van der Leun, ... Nature communications 12 (1), 7348, 2021 | 213 | 2021 |
| A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response O Krijgsman, P Roepman, W Zwart, JS Carroll, S Tian, FA de Snoo, ... Breast cancer research and treatment 133, 37-47, 2012 | 181 | 2012 |
| Intra‐and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts K Kemper, O Krijgsman, P Cornelissen‐Steijger, A Shahrabi, F Weeber, ... EMBO molecular medicine 7 (9), 1104-1118, 2015 | 160 | 2015 |
| Focal aberrations indicate EYA2 and hsa‐miR‐375 as oncogene and tumor suppressor in cervical carcinogenesis M Bierkens, O Krijgsman, SM Wilting, L Bosch, A Jaspers, GA Meijer, ... Genes, Chromosomes and Cancer 52 (1), 56-68, 2013 | 158 | 2013 |
| Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients EA Semenova, M Kwon, K Monkhorst, JY Song, R Bhaskaran, ... Cell reports 16 (3), 631-643, 2016 | 157 | 2016 |
| TSPYL5 suppresses p53 levels and function by physical interaction with USP7 MT Epping, LAT Meijer, O Krijgsman, JL Bos, PP Pandolfi, R Bernards Nature cell biology 13 (1), 102-108, 2011 | 151 | 2011 |
| PRAME expression and clinical outcome of breast cancer MT Epping, AAM Hart, AM Glas, O Krijgsman, R Bernards British journal of cancer 99 (3), 398-403, 2008 | 136 | 2008 |
| Integrative epigenetic taxonomy of primary prostate cancer S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ... Nature communications 9 (1), 4900, 2018 | 135 | 2018 |
| XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data RJC Kluin, K Kemper, T Kuilman, JR de Ruiter, V Iyer, JV Forment, ... BMC bioinformatics 19, 1-15, 2018 | 130 | 2018 |
| Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer P Roepman, HM Horlings, O Krijgsman, M Kok, JM Bueno-de-Mesquita, ... Clinical Cancer Research 15 (22), 7003-7011, 2009 | 119 | 2009 |
Blank cNetherlands Cancer InstitutePotvrđena adresa e-pošte na nki.nl
